See the published version of this article at Nutrition & Metabolism.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Milad Daneshi-Maskooni
Tehran University of Medical Sciences, School of Nutritional Sciences and Dietetics
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1373-1358
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Nutrition & Metabolism.
Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the effects of Bunium Persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels in overweight or obese T2DM patients.
Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups, namely BP (n=30) and placebo (n=30). The supplementation was one 1000 mg capsule 2 times /day BP with meals (lunch and dinner) for 8 weeks. Bodyweight, waist circumference, serum nesfatin-1, fasting blood sugar (FBS) and insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR), and Body Mass Index (BMI) were also calculated.
Results: In comparison with placebo, BP significantly decreased FBS, HOMA-IR, and BMI (P<0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P>0.05).
Conclusion: BP supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results.
Trial Registration: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752
Keywords
Type 2 diabetes, Bunium Persicum, Glucose indices, Lipids, Nesfatin-1
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 3
Posted 12 Jun, 2020
Published
On 26 Aug, 2020
No community comments so far
Editorial decision: Accept
On 15 Jun, 2020
Editor assigned
On 09 Jun, 2020
Submission checks complete
On 08 Jun, 2020
Editor invited
On 08 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 21 May, 2020
Review #2 received
Received 19 May, 2020
Reviewer #2 agreed
On 03 May, 2020
Review #1 received
Received 03 May, 2020
Reviewer #1 agreed
On 02 May, 2020
Reviewers invited
Invitations sent on 25 Apr, 2020
Editor assigned
On 23 Apr, 2020
Submission checks complete
On 22 Apr, 2020
Editor invited
On 22 Apr, 2020
No comments provided
Editorial decision: Major revision
On 21 Mar, 2020
Review #2 received
Received 08 Mar, 2020
Reviewer #2 agreed
On 25 Feb, 2020
Review #1 received
Received 02 Feb, 2020
Reviewer #1 agreed
On 31 Jan, 2020
Reviewers invited
Invitations sent on 29 Jan, 2020
Editor assigned
On 27 Jan, 2020
Editor invited
On 26 Jan, 2020
Submission checks complete
On 23 Jan, 2020
First submitted
On 21 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Nutrition & Metabolism. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Milad Daneshi-Maskooni
Tehran University of Medical Sciences, School of Nutritional Sciences and Dietetics
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1373-1358
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 3
Posted 12 Jun, 2020
Published
On 26 Aug, 2020
No community comments so far
Editorial decision: Accept
On 15 Jun, 2020
Editor assigned
On 09 Jun, 2020
Submission checks complete
On 08 Jun, 2020
Editor invited
On 08 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 21 May, 2020
Review #2 received
Received 19 May, 2020
Reviewer #2 agreed
On 03 May, 2020
Review #1 received
Received 03 May, 2020
Reviewer #1 agreed
On 02 May, 2020
Reviewers invited
Invitations sent on 25 Apr, 2020
Editor assigned
On 23 Apr, 2020
Submission checks complete
On 22 Apr, 2020
Editor invited
On 22 Apr, 2020
No comments provided
Editorial decision: Major revision
On 21 Mar, 2020
Review #2 received
Received 08 Mar, 2020
Reviewer #2 agreed
On 25 Feb, 2020
Review #1 received
Received 02 Feb, 2020
Reviewer #1 agreed
On 31 Jan, 2020
Reviewers invited
Invitations sent on 29 Jan, 2020
Editor assigned
On 27 Jan, 2020
Editor invited
On 26 Jan, 2020
Submission checks complete
On 23 Jan, 2020
First submitted
On 21 Jan, 2020
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Nutrition & Metabolism.
Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the effects of Bunium Persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels in overweight or obese T2DM patients.
Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups, namely BP (n=30) and placebo (n=30). The supplementation was one 1000 mg capsule 2 times /day BP with meals (lunch and dinner) for 8 weeks. Bodyweight, waist circumference, serum nesfatin-1, fasting blood sugar (FBS) and insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR), and Body Mass Index (BMI) were also calculated.
Results: In comparison with placebo, BP significantly decreased FBS, HOMA-IR, and BMI (P<0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P>0.05).
Conclusion: BP supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results.
Trial Registration: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752
Figure 1
Loading...